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Bone remodelling is related to coordinated phases of bone resorption and bone apposition allowing the
maintenance of bone integrity, the phosphocalcic homoeostasis all along the life and consequently the
bone adaptation to mechanical constraints or/and to endocrine ﬂuctuations. Unfortunately, bone is a
frequent site of tumour development originated from bone cell lineages (primary bone tumours: bone
sarcomas) or from nonosseous origins (bone metastases: carcinomas). These tumour cells disrupt the
balance between osteoblast and osteoclast activities resulting in a disturbed bone remodelling
weakening the bone tissue, in a strongly altered bone microenvironment and consequently facilitating
the tumour growth. At the early stage of tumour development, osteoclast differentiation and
recruitment of mature osteoclasts are strongly activated resulting in a strong bone matrix degradation
and release of numerous growth factors initially stored into this organic/calciﬁed matrix. In turn these
soluble factors stimulate the proliferation of tumour cells and exacerbate their migration and their
ability to initiate metastases. Because Receptor Activator of NFkB Ligand (RANKL) is absolutely required
for in vivo osteoclastogenesis, its role in the bone tumour growth has been immediately pointed out
and has consequently allowed the development of new targeted therapies of these malignant diseases.
The present review summarises the role of RANKL in the bone tumour microenvironment, the most
recent pre-clinical and clinical evidences of its targeting in bone metastases and bone sarcomas. The
following sections position RANKL targeted therapy among the other anti-resorptive therapies available
and underline the future directions which are currently under investigations.
& 2012 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bone is a very dynamic tissue resulting from coordinated phases
of formation and resorption called bone remodelling. Additional to its
role in phosphocalcic homoeostasis, bone remodelling process is
necessary for bone growth, for renewal of cellular and extracellular
matrix components to adapt bone organisation to the various
biological and mechanical constraints [1–3]. Bone remodelling then
leads to the renewal of around 10% of total bone mass each year in
human. This metabolic process is based on a molecular crosstalk
occurring between osteoblasts involved in bone apposition and
osteoclasts specialized in bone resorption. Osteoclasts are multi-
nucleated cells that originated from hematopoietic stem cells [4–6]. This is an open access article un
thophysiology of Bone
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s.frwhereas osteoblasts are derived from bone marrow mesenchymal
stem cells [3,7,8]. Osteoblasts control osteoclast differentiation and
activation through a very complex network of soluble factors which
act in combination with various hormones produced by endocrine
system even if contacts between both cell types also strongly
contribute to full activation of osteoclasts [9,10]. Reciprocity between
osteoblasts and osteoclasts can be observed as shown by bidirectional
signalling limiting osteoclast activities and stimulating osteoblast
differentiation [11].
Bone remodelling can be dysregulated by oncologic events
originated from bone cells (primary bone tumours: osteosarcoma,
chondrosarcoma, Ewing’s sarcoma, etc.) or from nonosseous origins
(bone metastases). Large series revealed that around 0.2% of all
neoplasms are bone sarcomas and two new primary bone tumours
arise per 100,000 persons a year [12]. Bone tissue is then the most
frequent site of their ﬁrst relapse and consequently, the incidence of
bone metastases is relatively high and is dependent on the cancer
cell types (i.e. in 70–80% of patients with breast or prostate cancer,
in 40% of patients with lung metastases or with kidney cancer). Boneder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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plications named skeletal-related events (SREs) and have a strong
deleterious impact on the quality of life. SREs include pathological
fractures or spinal cord compression and exacerbated bone pains. All
bone tumours disrupt the equilibrium between bone apposition and
bone resorption leading to the ﬁrst stop of the tumour development
to an osteolytic process followed or not by bone forming lesions.
Soluble mediators stored initially into the bone matrix contribute in
turn to stimulate the tumour growth and to maintain the vicious
cycle between bone and tumour cells [13]. The loss of equilibrium
between bone formation and degradation combined with an osteo-
mimetism behaviour of cancer cells (cancer cells acquire bone-like
properties) explains the diversity of histological features (osteolytic
or bone forming tumours) of bone metastases [14]. Additionally, the
modulation of bone micro-environment (‘‘niche’’ concept) by cancer
cells is beneﬁcial for their proliferation and also contributes to the
drug resistance patterns [15].
In the late 1990s, two research groups in Japan and in USA have
identiﬁed a truncated TNF receptor-like molecule (named OPG for
osteoprotegerin, TNFRSF11B) inducing marked osteopetrosis pheno-
type when overexpressed in transgenic mice [16,17]. One year later,
RANKL (Receptor Activator of Nuclear Factor kB Ligand or TNFSF11)
has been identiﬁed as a ligand for OPG [18,19]. In a few years, OPG/
RANKL couple became the principal system regulating osteoclasto-
genesis and bone resorption and has impressively stimulated theWT
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Fig. 1. RANKL is absolutely required for osteoclast differentiation in vivo as revealed by th
exhibited by RANKL knockout (RANKL/) compared to wild type (WT) C57BL6 mice a
soluble forms) which binds to membrane RANK expressed by osteoclast precursors, O
interactions and then inhibits bone resorption. The lack of RANKL results in a disturbed b
resorption compared to the control mice.development of OPG/RANKL targeting agents for the treatment of
osteolytic disorders in oncologic contexts or not competing with
bisphosphonates, a well admitted drug class for the treatment of bone
loss [13,19–23].
In all bone cancers, a strong relationship between tumour cells
and bone micro-environment has been then clearly established,
facilitating the tumour development and/or the metastatic process.
These speciﬁc communication pathways have strongly stimulated
the research and development programs to design new drugs to
treat oncologic bone diseases and have led speciﬁcally to the
development of therapies targeting RANKL. The present review
summarises the most recent progresses in the treatment of bone
cancers based on RANKL targeting and underlines the future
directions which are currently under pre-clinical investigations.2. OPG, RANK and RANKL are key protagonists controlling
osteoclast biology and bone remodelling
The critical function of OPG in osteoclastogenesis has been initially
revealed by the osteopetrotic phenotype of mice overexpressing it
[18,19]. In contrast, OPG deﬁcient mice exhibit osteoporotic pheno-
type which is totally reversed by administration of recombinant OPG
[24]. RANKL has been identiﬁed as the main ligand of OPG known to
bind RANK (TNFRSF11A), a transmembrane receptor of the TNFR            RANKL-/-
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one remodelling characterised by an excessive bone formation and a reduced bone
D. Heymann / Journal of Bone Oncology 1 (2012) 2–114superfamily [25]. RANKL transgenic mice and RANKL knockout mice
are respectively osteoporotic and osteopetrotic (Fig. 1). In fact,
membrane and soluble RANKL produced by osteoblasts interact with
RANK expressed on monocyte lineage and osteoclast precursors,
induces osteoclast differentiation and consequently activates bone
resorption [23, Fig. 1]. Discovery of the RANK/RANKL signalling
pathway through NFkB in the osteoclast has clearly provided new
insights into the mechanisms of osteoclastogenesis and how hormo-
nal networks impact bone remodelling [23–26]. OPG is the third
protagonists and acts as a decoy receptor, binds to RANKL, inhibits
RANK–RANKL interactions and in ﬁne is a strong anti-resorptive
agent. The balance between bone resorption and bone apposition
consequently depends on the ratio OPG/RANKL (Fig. 1). For instance,
the relative equilibrium between OPG and RANKL levels results in a
stable bone mass, and in contrast for instance to RANKL knockout
where bone remodelling is in favour of excessive bone formation due
a marked reduction of osteoclastogenesis (Fig. 1). Similarly, a clear
relationship has been established between RANKL/OPG ratio and the
severity of osteolysis in oncologic diseases as in benign diseases [27].
It is now admitted that RANKL is absolutely required for osteoclas-
togenesis in vivo even if RANKL can be substituted in vitro by other
ligands such as TNFa [28]. As the other TNF members, OPG, RANK
and RANKL exhibit very complex stoichiometric characteristics.
Indeed, OPG is a dimeric molecule, but it can even act as a monomer
and RANL and RANK are homotrimeric complexes [20,28–30].
Additionally, OPG biology is more complex than those initially
described and possesses numerous ligands such as other TNF Related
Apoptosis Inducing Ligand (TRAIL) [31], proteoglycans [32] and
glycosaminoglycans [33,34], von Willebrand factor [35], complex VIII
[36] which modulate its own activity.Osteosarcoma
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Fig. 2. RANK is expressed by numerous tumour cell type. (A) Main tumour cell types exp
prostate carcinoma and thyroid carcinoma [51]. (C) RANKL is also expressed by cancer3. OPG, RANK and RANKL contribute to the vicious cycle
established between tumour cells and bone
microenvironment: evidences for sarcomas and carcinomas
In bone microenvironment, OPG/RANK/RANKL molecular triad
is not solely expressed by bone cells. Whether OPG is considered as
a ubiquitary receptor [20], membrane RANK is expressed by
various tumour cells that originate from primary bone tumours
or bone metastases, from mesenchymal and epithelial origin
(Fig. 2A and B). A recent study showed that more than 80% of
bone metastases from solid tumours are RANK positive as revealed
by immunohistochemistry [42,43]. RANK is also expressed in more
than 50% of human osteosarcoma specimens, with preferential
expression in osteosarcomas that develop in pathological bone and
are bad responders to chemotherapy [39]. These observations then
identify tumour cells as potential RANKL targets. In addition to its
expression by osteoblasts and bone marrow stromal cells, RANKL is
produced similarly as RANK by numerous cancer cell types from
various origins (Fig. 2C). RANKL expression is modulated by a lot of
cytokines, hormones [20] and by hypoxia dysregulating bone
remodelling, a common feature of malignant tumours [77]. Indeed,
the invasion of bone tissue by a primary or metastatic tumour cell
precociously affects the balance between bone resorption and bone
formation. According to the tumour entities, tumour-derived
factors (IGF, BMP, etc.) can stimulate osteoblast differentiation
and activation and lead to tumour associated osteoblastic lesions
(Fig. 3) or in contrast, RANKL released by tumour cells can activate
osteoclastogenesis and the recruitment of mature osteoclasts
resulting in osteolytic lesions. The co-existence of both phenomena
leads to the formation of mixed osteoblastic/osteoclastic lesions. In27, 57Osteosarcoma
27Giant cell tumor
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Fig. 3. Direct and indirect role of RANKL in bone tumour development. RANKL contributes to the development of bone tumours via the activation of osteoclastogenesis and
bone resorption deﬁning an osteoclast-dependent pathway. RANKL also can bind directly RANK-expressing tumour cells, stimulating epithelial mesenchymal transition,
cell migration and then identifying an independent osteoclast. Tumour cells dysregulate the balance between osteoblasts and osteoclasts, resulting in osteolytic,
osteoblastic or osteoblastic–osteoclastic mixed lesions according the tumour cell type.
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nents and soluble mediators (TGFb, etc.) are initially trapped in the
bone matrix and stimulate proliferation of tumour cells and then
the growth of tumour mass (Fig. 3). This mechanism is deﬁned as
the osteoclast-dependent role of RANK/RANKL axis in tumorigen-
esis. However, RANK/RANKL axis inﬂuences tumorigenesis through
osteoclast-independent pathway (Fig. 3). RANKL produced by bone
microenvironment constitutes a fertile soil for RANK-positive
tumour cells. Initially proposed by Paget at the end of 1900 the
concept of the seed and soil for primary and secondary bone
tumours has been strengthened by the discovery of RANKL and
RANKL partly explains why various tumours preferentially metas-
tasise to bone. RANKL released by osteoblasts and bone marrow
stromal cells creates a cytokine gradient between bone site and
extraosseous sites and triggers the migration of RANK-positive
tumours cells. Interestingly, numerous tumour cells expressed
functional RANK as shown by the signal transduction (P-ERK1/2,
P-P38, P-IkB, etc.) induced by RANKL [39,47,50]. The ﬁrst evidence
of this mechanism has been established by Jones et al. [45] and has
been now described as prostate carcinoma [45,47,48], breast
carcinoma [45], oral squamous carcinoma [50], lung cancer cells
[52] and melanoma [45]. The implication of RANK/RANKL axis in
tumour cell migration has been conﬁrmed by exploration in
human samples. Indeed, the levels of RANK expressed by primary
tumour cells are directly related to the occurrence of bone
metastases in solid tumours and more speciﬁcally in breast,
prostate and melanoma [42–44]. Furthermore, RANK expression
could be considered as an independent predictor of poor prognosisin breast cancer patients with bone metastasis in contrast with
visceral metastasis for which no correlation has been shown [77].
Similarly, increased RANKL expression is related to the migration of
renal carcinoma [53]. Whether the role of functional RANK expres-
sion has been clariﬁed for carcinomas, its role in the pathogenesis
of sarcomas is not fully understood. Indeed, it has been shown that
osteosarcoma cells express the RANK protein [39]. RANK signalling,
under the action of RANKL, results in the modulation of a panel of
more than 70 speciﬁc genes demonstrating that osteosarcoma cells
are therefore RANKL targets [40]. Wittrant et al. [38] showed that
RANKL directly induces BMP-2 expression in RANK positive osteo-
sarcoma cells and may contribute by this way to the osteoblastic
lesions characteristic of osteosarcomas. More recently, Lee et al.
observed that RANKL expression is correlated to clinical behaviour
of patients suffering from high-grade osteosarcoma [57].4. RANK/RANKL axis is involved in the tumorigenic process
RANK/RANKL axis is associated with the bone metastastic pro-
cess, and as several arguments point out it is also involved in the
tumorigenicity process itself. RANK/RANKL may participate in the
initial oncogenic program as shown by high expression of RANK in
melanoma-initiating cells compared to the other melanoma cells
[54]. Epithelial mesenchymal transition (EMT) is the ﬁrst step
allowing the extravasation and migration of carcinoma cells and
RANKL appears clearly involved in this process. Indeed, Yamada et al.
show that RANKL promotes EMT and induces angiogenesis
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[78]. RANKL has also a strong impact on normal epithelial cells as
shown by its effect on mammary gland development evidenced by a
lactation defect in RANKL knockout mice [79,80]. In fact, RANKL
promotes the proliferation and survival of mammary epithelial cells
[79–82] and RANK expression increases during the gestation more
speciﬁcally at ductal branch points [82]. More interestingly, whether
RANKL or RANK overexpression in the mammary epithelial cells
results in aberrant proliferation and hyperplasia of mammary glands,
it directly correlates with preneoplasias and the development of
spontaneous mammary tumours [83,84]. Several authors hypothe-
sised that RANKL may act as a paracrine factor for mammary stem
cells [85,86]. Consequently, blockade of RANKL signiﬁcantly reduces
the occurrence of mammary tumours [84]. Overall, these data give
clear evidences that the RANK/RANKL axis contributes to the initial
steps of tumorigenesis at least for mammary glands, to the dis-
semination process of carcinoma cells and to the establishment of
bone metastases.5. Therapies targeting RANK/RANKL axis for patients suffering
from bone tumours: pre-clinical and clinical arguments
Given this context, targeting of RANKL signalling with its
decoy receptor OPG or with a soluble form of its membranous
receptor RANK (RANK-Fc) inhibits tumour associated osteolysis in
several experimental bone tumour models, including rat and
mouse primary bone tumours and bone metastases. Indeed,Table 1
Summary of the main clinical trials in oncology assessing anti-RANKL therapies.
Clinical trials drug assessed Cancer Numb
patien
includ
Phase I OPG recombinant Bone metastases (Breast) 26
Myeloma 28
Phase I, Denosumab Bone metastases (Breast) 29
Myeloma 25
Randomized, double blind Bone metastases (excluding
breast, prostate and
myeloma)
886
Denosumab versus zoledronate 890
Randomized, double blind Bone metastases (Breast) 1026
Denosumab versus zoledronate 1020
Phase II, Denosumab with and
without bisphosphonate exposure
Bone metastases 366
Denosumab vs placebo and adjuvant
aromatase inhibitors
Non-metastatic
breast cancer
127 (t
125 (p
Phase II, randomized trial
Denosumab after i.v.
bisphosphonates
Bone metastases (prostate,
breast cancers and other
neoplasms)
111
Phase II Denosumab Myeloma 96
Phase II, Randomized Denosumad
after i.v. bisphosphonates
Bone metastases (Prostate) 111
Double-blind study Denosumad and
androgen-deprivation
Prostate cancer 734 p
Double-blind study Denosumab and
androgen-deprivation
Prostate cancer 734 p
Phase III Denosumab in castration-
resistant patients
Prostate cancer 716 p
Phase III, Denosumab versus
zoledronate in castration-resistant
patients
Prostate cancer 950 p
Phase II Denosumab Giant cell tumours of bone 37OPG and RANK-Fc administered by nonviral gene transfer or as
recombinant molecules are effective in preventing the formation
of osteolytic lesions associated with osteosarcoma development
and in reducing the tumour incidence leading to a signiﬁcant
increase of animal survival [87,88]. Moreover, recent experiments
demonstrated that RNA interference strategy targeting RANKL
improved the tumour response to chemotherapy in a murine
model of osteosarcoma [89]. Similarly, administration of recom-
binant OPG-Fc or RANK-Fc has been investigated in numerous
murine models of bone metastases [20,23,79] and conﬁrms that
blockade of the RANK/RANKL axis is extremely efﬁcient in pre-
clinical assessment to prevent tumour-induced osteolysis, to
reduce tumour growth and to improve the survival rate. Accord-
ing these pre-clinical proofs of concept, recombinant OPG (OPG-
Fc) has been evaluated in postmenopausal [90] and in patients
suffering from myeloma and osteolytic bone metastases (Table 1).
Results demonstrated that OPG was well tolerated and demon-
strated the efﬁcacy of a single injection of OPG, which strongly
reduced bone turnover for a sustained period and suppressed
bone resorption as indicated by the decrease of bone resorption
markers (urinary NTX/creatinine); these effects were comparable
to those obtained with pamidronate. However, due to the risk of
immune modulation of OPG through its binding to TRAIL [31] and
other ligands [32–36], a fully human monoclonal antibody (IgG2)
speciﬁcally targeting soluble and membrane RANKL has been
developed [92,93]. Clinical data in osteoporotic patients revealed
that denosumab was well tolerated with no related serious
adverse events occurred and that a single-dose (0.01–3.0 mg/kg)er of
ts
ed
Doses References
s.c. 0.1–3 mg/kg [91]
Denosumab s.c. 0.1–3 mg/Kg Pamidronate
90m g i.v.
[95]
Denosumab s.c. 120 mg monthly
Zoledronate i.v. 4 mg monthly
[96]
Denosumab s.c. 120 mg monthly
Zoledronate i.v. 4 mg monthly
[97]
Denosumab s.c. 60 or 180 mg every 12
weeks Denosumab s.c. 30, 120, or 180 mg
every 4 weeks
[98–100]
reated)
lacebo)
Denosumab s.c. 60 mg every 6 weeks [101, 102]
Denosumab s.c. 180 mg every 4 or 12 weeks [103]
Denosumab s.c.120 mg on days 1, 8, and 15
(loading doses) of cycle 1 (28 day), and then
on study day 29 (day 1 of cycle 2) and on day
1 of every cycle (28 day) thereafter
[104]
Denosumab s.c. 180 mg every 4 or 12 weeks [105]
er group Denosumab s.c. 60 mg every 6 months [106]
er group Denosumab s.c. 60 mg every 6 months [107]
er group Denosumab s.c. 120 mg every 4 weeks [108]
er group Denosumab s.c. 120 mg or zoledronate 4 mg
i.v. every 4 weeks
[109]
Denosumab s.c. 120 mg monthly [110]
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in bone turnover [92,93]. This antibody, named denosumab,
only recognises the human protein and its nonhuman-primate
homologue and its administration in chimeric mice expressing
murine/human leads to a strong inhibition of bone resorption
concomitantly to an increase of the bone mineral density [94].
Numerous clinical trials (phase II and phase III) have been then
designed to evaluate the efﬁcacy of denosumab in oncology
mainly in breast and prostate bone metastases (Table 1). These
studies revealed that denosumab reduced signiﬁcantly bone turn-
over markers similarly to osteoporotic patients. More speciﬁcally,
it reduced levels of uNTX/Cr as well as serum TRAP5b thus
showing a marked inhibition of osteoclastogenesis. According to
the results obtained, the recommendations for the use of denosu-
mab are 120 mg s.c. every 4 months in oncology. Using this dose,
bone resorption markers are suppressed around 90% in most
patients independent of the tumour types [103]. Various studies
have been set up to compare denosumab versus bisphosphonate
treatment mainly zoledronic acid [95–97,103,109]. Single dose of
pamidronate for instance (90 mg i.v.) reduced in a similar inten-
sity the levels of bone resorption markers but the effects of
denosumab were more sustained [95]. Phase III study demon-
strated that denosumab signiﬁcantly delayed the time of ﬁrst
SRE (Skeletal Related Event) but also the risk of multiple SRE
and whether zoledronic acid showed similar effects, statistical
analyses are in favour of superiority for denosumab (Table 1).
The time of disease progression and the overall survival rate
were similar between anti-RANKL treatment and bisphosphonate.
Zoledronic acid treatment requires a strict monitoring of kidney
function due to its toxicity in contrast to denosumab even if a
greater hypocalcemia requiring speciﬁc monitoring has been
classically observed after denosumab treatment [111]. In addition
to the phase acute phase reaction observed in patients after the
ﬁrst administration of zoledronic acid, osteonecrosis of the jaw
occurred infrequently after long-term treatment by nitrogen-
bisphosphonates, in around 2% of patients [97,108,109,112–115].
This incidence appears similar in bisphosphonate- and denosumab-
treated patients. Consequently, the establishment of meticulous oral
hygiene and surgical procedures prior to the administration of
bisphosphonates and denosumab is the best method forMMP9 inhibito
Cathepsin K inhib
Antisense oligodeo
Osteoclast
precursors
Quiescent 
osteoclast
Fusion and
differentiation
Anti-RANKL antibody
OPG, RANK-Fc
Blocking peptides
Fig. 4. Therapeutic arsenals currently used or in development targeting osteoclast linea
differentiation and/or their activation by blocking RANKL binding to RANK, by signal tpreventing osteonecrosis of the jaw; prevention being better than
treatment. In all studies, denosumab was well tolerated with the
convenience of a subcutaneous administration and no require-
ment for renal monitoring. Overall, these clinical trials demon-
strated that denosumab represents a potential treatment option
economically viable for patients with bone metastases [116]. Very
recently, a novel anti-RANKL antibodies derived from camelidae
has been assessed in postmenopausal patients [117]. The results
from this Phase I trial, including the one year follow-up informa-
tion, indicate that ALX-0141 is well tolerated and can be admi-
nistered safely over a wide range of doses. ALX-0141 exhibited
a strong and sustained inhibitory effect on bone resorption
markers.6. The other anti-resorptive in therapies of bone cancer
Bisphosphonates have been used successfully for many years to
treat the skeletal complications associated with the benign and
malignant bone diseases [118–121]. Bisphosphonates became pro-
gressively a standard treatment for cancer-associated with hypercal-
cemia and to control metastatic bone pain. Bisphosphonates are
chemical compounds based on a phosphorus–carbon–phosphorus
template and are characterised by their strong afﬁnity for bone
hydroxyapatite crystals and their anti-resorptive potency. Three
families of bisphosphonate have been produced: the ﬁrst possesses
simple substituents attached to the central carbon and inhibits
weakly the bone resorption; the second family possesses an aliphatic
side chain containing a single nitrogen atom and exerts a more
potent anti-resorptive activity; the third generation contains a
heterocyclic substituent with one or two nitrogen atoms and
are powerful bone resorption inhibitors and anti-tumour agents
[118,119]. The members of the ﬁrst family which do not contain
nitrogen atom are metabolised in cytotoxic analogues of ATP leading
to cell death. Nitrogen-containing bisphosphonates inhibit the activ-
ity of two enzymes involved in the mevalonate pathway: farnesyl
diphosphate synthase (FPP) and geranylgeranyl diphosphate
synthase (GGPP). This inhibition results in osteoclast apoptosis by
the strong reduction of the prenylation process, the loss of osteo-
clastic rufﬂed border and modiﬁcations of cell cytoplasmic actin ringBisphosphonates
Integrin inhibitors
rs (migration)
itors (resorption)
xyribonucleotides
Mature and active
osteoclast
Survival 
and adhesion
NFκB inhibitors
Tyrosine kinase inhibitors
Signal tranduction inhibitors
ge to treat bone tumours. These therapeutic approaches target osteoclasts, their
ransduction, cell adhesion and migration or enzymatic activities.
D. Heymann / Journal of Bone Oncology 1 (2012) 2–118[118,119]. Additionally, nitrogen-containing bisphosphonates exert
direct activities on tumour cells (breast, prostate, lung renal carci-
noma, osteosarcoma, chondrosarcoma, etc.) through the inhibition of
prenylation mechanimwhich induces tumour-cell apoptosis, inhibits
cell proliferation, modulates tumour-cell adhesion and inhibits
tumour-cell dissemination [118–124]. Thus, bisphosphonates inhibit
the development of bone tumours through direct activity on tumour
cells and indirect activity on osteoclasts. Pre-clinical studies revealed
the therapeutic beneﬁts of bisphosphonates for the treatments of
primary bone tumours and bone metastases alone and in combina-
tion with chemotherapy or signalling pathway inhibitors [125–133].
Clinical trials have clearly conﬁrmed their therapeutic interests
(Table 1).
Since many decades, bone tumours have stimulated imagination
of researchers and numerous therapeutic alternatives have been
proposed [134,135, Fig. 4]. The better knowledge of OPG/RANK/
RANKL system leads to the development of peptides mimicking
OPG and blocking RANK–RANKL interactions [136–139]. Inhibitors
of NF-KB signalling showed interesting anti-resorptive activities
[140–143]. The targeting of integrins more speciﬁcally avb3
strongly reduced the osteolytic process and the development of
bone tumours [144–150]. Speciﬁc blockade of enzymatic activities
has been envisaged with a great success. MMP9 involved in
osteoclast migration and its targeting blocked by antisense oligo-
deoxyribonucleotide strongly affects osteoclast migration and
resorption [151]. Cathepsin K, a key cysteine-proteinase related to
osteolytic process [152,153], stimulates a huge enthusiasm in the
world of bone research. Several companies have then developed
chemical inhibitors of cathepsin K to treat malignant and non-
malignant bone loss with interesting results [154–157]. Thus, forty-
three women suffering from breast metastatic disease have been
recently randomized in a double-blind study to evaluate the impact
of oral cathepsin K inhibitors [odanacatib 5 mg daily for 4 weeks
or 4 mg zoledronic acid i.v] on bone resorption markers [157].
Odanacatib appeared generally safe and well tolerated and has
suppressed osteolytic markers similar to zoledronic acid after
4 weeks of treatment. These results strengthen the therapeutic
interest of cathepsin K for oncologic bone loss.7. Conclusions
Bone tissue massively attracts tumour cells where they ﬁnd a
favourable environment to maintain the stem cell dormancy and
where they ﬁnd a fertile ground for their development. This ‘‘fatal
attraction’’ linked to the speciﬁc bone niche has boosted therapeutic
innovations targeting the tumour cells and/or their microenviron-
ment [158]. During the last past decade, RANK/RANKL axis emerged
in bone biology as predominant protagonists of bone remodelling
and as therapeutic targets of bone loss diseases. Better knowledge of
RANK/RANKL biology will better deﬁne their relevance as biomarkers
in bone oncology, and a complete cartography of RANK expression
will be very useful to predict good responders to anti-RANKL
therapies. Although anti-RANKL therapy progressively competes
with approaches by bisphosphonates, a lot of prospect including
signal transduction inhibitors, peptides or enzymatic inhibitors has
been already identiﬁed and pre-clinical data as well as clinical trials
allow personalised therapies in bone oncology.Acknowledgments
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